Immunic Inc (IMUX)

[NRS]

News at 3:35am today: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis. 92% of MS patients had no disability worsening after 3 years on lead oral drug.
https://finance.yahoo.com/news/immunic-reports-positive-long-term-103000989.html
On 5/29/25: D. Boral Capital analyst Jason Kolvbert maintains Immunic with a Buy and maintains $10 price target.